21 November 2017
News and Views
Links and Services
A study in the latest issue of Inflammatory Bowel Diseases examines the efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease.
Intestinal Behçet disease is characterized by intestinal inflammation with round and oval ulcers
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors